Search results for: Pricing and Reimbursement
Filter search results
The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
1 September 2020
…full benefits, referred to as their ‘broader value’, can lead to undervaluing vaccines. This, in turn, may lead to suboptimal vaccine development, recommendation, and reimbursement decisions. To address this issue,…
Navigating the Landscape of Digital Health – United Kingdom
16 December 2022
…value assessment and reimbursement, and efforts to increase the digital literacy of the general population and the health workforce. We provide lessons learned that may be of value to decision-makers…
Reimagining Prevention for a Healthier, More Prosperous Society
29 November 2023, 3:00pm
…NHSA is a northern body working at a national and international level for the health and wealth benefit of Northern England. Hannah has also co-authored several seminal reports, including the…
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…publications and several books on female cancers and pathologic testing methods and issues. WATCH IT ON DEMAND This project was commissioned and funded by Takeda Pharmaceuticals International AG….
OHE at ISPOR 2024
5 May 2024, 12:00am
…the Dimensions of Sustainable Global Biosimilars Markets Mireia Jofre-Bonet 06 May 2024 10:30 EDT Poster Session Value Assessment and Reimbursement of Early Treatment for Prevention in Chronic Progressive Diseases: Are…
Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
10 June 2024
…experts, research and innovation funders, innovators in research institutes and industry, regulators, health technology assessment expertise, policymakers and payers, and the patient voice. TPP development has two key stages: inception…
Dr. Inmaculada Hernandez
3 September 2024
Dr. Inmaculada (Inma) Hernandez is a Professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hernandez is a pharmacist and a scholar whose…
Personalised Medicine: Is it an Oil-Rush or Oil-Spill?
3 February 2020, 12:00am
…acquired in an interpretable manner, is useful. However, it is also disruptive and has the potential to challenge many existing institutions, regulations and pricing patterns. Some empirical examples will be…
2010 Lecture: US Health Care Reform
27 May 2010
…and the implications for both public and private programs Changes in the nature and extent of the demand for services that may affect, for example, preventive care, primary care, and…